These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 7624492)
1. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Neyens LG; Alpherts WC; Aldenkamp AP Prog Neuropsychopharmacol Biol Psychiatry; 1995 May; 19(3):411-9. PubMed ID: 7624492 [TBL] [Abstract][Full Text] [Related]
2. Levetiracetam: treatment in epilepsy. Ben-Menachem E Expert Opin Pharmacother; 2003 Nov; 4(11):2079-88. PubMed ID: 14596661 [TBL] [Abstract][Full Text] [Related]
3. The place of levetiracetam in the treatment of epilepsy. Leppik IE Epilepsia; 2001; 42 Suppl 4():44-5. PubMed ID: 11564126 [No Abstract] [Full Text] [Related]
4. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Sisodiya SM; Sander JW; Patsalos PN Epilepsy Res; 2002 Feb; 48(3):217-9. PubMed ID: 11904240 [TBL] [Abstract][Full Text] [Related]
5. Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study. López-Góngora M; Martínez-Domeño A; García C; Escartín A Epileptic Disord; 2008 Dec; 10(4):297-305. PubMed ID: 19017572 [TBL] [Abstract][Full Text] [Related]
6. Role of levetiracetam in the treatment of epilepsy. Brodie MJ; French JA Epileptic Disord; 2003 May; 5 Suppl 1():S65-72. PubMed ID: 12915344 [TBL] [Abstract][Full Text] [Related]
7. A new antiepileptic drug. Shorvon SD; van Rijckevorsel K J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):426-9. PubMed ID: 11909894 [No Abstract] [Full Text] [Related]
8. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Chaisewikul R; Privitera MD; Hutton JL; Marson AG Cochrane Database Syst Rev; 2001; (1):CD001901. PubMed ID: 11279737 [TBL] [Abstract][Full Text] [Related]
9. Effect of levetiracetam monotherapy on background EEG activity and cognition in drug-naïve epilepsy patients. Cho JR; Koo DL; Joo EY; Yoon SM; Ju E; Lee J; Kim DY; Hong SB Clin Neurophysiol; 2012 May; 123(5):883-91. PubMed ID: 22000706 [TBL] [Abstract][Full Text] [Related]
10. Continuous subcutaneous use of levetiracetam: a retrospective review of tolerability and clinical effects. Rémi C; Lorenzl S; Vyhnalek B; Rastorfer K; Feddersen B J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):371-7. PubMed ID: 25313924 [TBL] [Abstract][Full Text] [Related]
11. Long-term continuation of levetiracetam in patients with refractory epilepsy. Krakow K; Walker M; Otoul C; Sander JW Neurology; 2001 Jun; 56(12):1772-4. PubMed ID: 11425954 [TBL] [Abstract][Full Text] [Related]
12. Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study. Betts T; Yarrow H; Greenhill L; Barrett M Seizure; 2003 Apr; 12(3):136-40. PubMed ID: 12651077 [TBL] [Abstract][Full Text] [Related]
13. An assessment of levetiracetam as an anti-epileptic drug. Jain KK Expert Opin Investig Drugs; 2000 Jul; 9(7):1611-24. PubMed ID: 11060765 [TBL] [Abstract][Full Text] [Related]
14. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Levisohn PM; Mintz M; Hunter SJ; Yang H; Jones J; Epilepsia; 2009 Nov; 50(11):2377-89. PubMed ID: 19702752 [TBL] [Abstract][Full Text] [Related]